share_log

Alliance Global Partners Maintains Buy on Vivos Therapeutics, Lowers Price Target to $6

Alliance Global Partners Maintains Buy on Vivos Therapeutics, Lowers Price Target to $6

Alliance global partners维持对vivos therapeutics的买入评级,调低目标价至6美元。
Benzinga ·  2024/11/19 08:58  · 评级/大行评级

Alliance Global Partners analyst Scott Henry maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $8.25 to $6.

Alliance Global Partners分析师斯科特·亨利维持Vivos Therapeutics(纳斯达克股票代码:VVOS)的买入并将目标股价从8.25美元下调至6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发